ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0262444 | disorders of the dental system that exist at, and usually before, birth regardless of their causation. | Dental Abnormality|DENTAL ABNORMALITY, NOS|Dental abnormality|Abnormal teeth|Dental abnormalities|Tooth abnormalities|Dental anomalies|Abnormality of the teeth|Abnormal dentition|Abnormality of the dentition|abnormalities dental|congenital dentition disorder|dental abnormality | Abnormality of the dentition |
C0447309 | null | Entire vestibular surface of tooth (body structure)|Entire vestibular surface of tooth|Entire buccal surface|Entire labial surface | Entire vestibular surface of tooth |
C0040442 | The collective tissues from which an entire tooth is formed, including the DENTAL SAC; ENAMEL ORGAN; and DENTAL PAPILLA. (From Jablonski, Dictionary of Dentistry, 1992) | Tooth Bud|Germ, Tooth|Tooth bud (body structure)|Germs, Tooth|tooth germ|Tooth Germs|Tooth bud | Tooth Germ |
C0597423 | A type of fat with certain chemical properties that is usually solid at room temperature. Most saturated fats come from animal food products, but some plant oils, such as palm and coconut oil, also contain high levels. Eating saturated fat increases the level of cholesterol in the blood and the risk of heart disease. | Acids, Saturated Fatty|saturated fatty acid|Saturated fat (substance)|saturated fatty acids|acids fatty saturated|Fatty Acids, Saturated|Saturated Fatty Acid|fat saturated|Saturated fat|saturated fat|Saturated fatty acid|Saturated fatty acid (substance)|Saturated fatty acid, NOS|Saturated Fatty Acids|fats saturated | Saturated fat |
C1138412 | A diet typical of the Mediterranean region characterized by a pattern high in fruits and vegetables, EDIBLE GRAIN and bread, potatoes, poultry, beans, nuts, olive oil and fish while low in red meat and dairy and moderate in alcohol consumption. | Diets, Mediterranean|diet mediterranean|Mediterranean Diet|Mediterranean Diets|mediterranean diets|mediterranean diet | Diet, Mediterranean |
C0012155 | Regular course of eating and drinking adopted by a person or animal. | DIETS|Dietary|Dietary finding|diet|regular diet?|Diet|Diet, NOS|diets|Dietary finding (finding)|Diets | Diet |
C0033554 | A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. | prostaglandin|prostanoid|PG|Prostaglandin (substance)|prostanoids|PG - Prostaglandin|PROSTAGLANDINS|Prostaglandin, NOS|prostaglandins|Product containing prostaglandin (product)|Prostanoids|Prostaglandins|Prostaglandin|Prostaglandin-containing product|Prostanoid|Prostanoid (substance) | Prostaglandins |
C0666003 | null | Levormeloxifene|LEVORMELOXIFENE|1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine|1-(2-(p-(trans-7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine | levormeloxifene |
C0039286 | One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. | (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine|Tamoxifeno|Tamoxifen-containing product|Tamoxifen (substance)|Tamoxifen|Product containing tamoxifen (medicinal product)|TAMOXIFEN|1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene|Tamoxifenum|1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|Tamoxifène|TAM|1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine|tamoxifen|Tamoxifene|Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)- | tamoxifen |
C0346070 | null | Multiple angiomatous nevi of skin (disorder)|Multiple strawberry nevi|Multiple haemangiomatosis|Multiple angiomatous naevi of skin|Multiple hemangiomatosis|Multiple strawberry naevi | Multiple angiomatous nevi of skin |
C0029939 | The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. | Ovarian structure (body structure)|Female gonad|ovary|ovarian structure|Genital System, Female, Ovary|Ovary|Ovarian structure|OVARIES|Ovary, NOS|Female gonad, NOS|Ovarium|ovaries|female gonad|Ovaries|OVARY | Ovary |
C0014145 | An unusual and aggressive tumor of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumor found in children. It is characterized by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (Schiller-Duval body). The tumor is rarely bilateral. Before the use of combination chemotherapy, the tumor was almost invariably fatal. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1189) | Infantile embryonal carcinoma|Polyvesicular vitelline tumour|Yolk Sac Tumors|ENDODERMAL SINUS TUMOR|Embryonal carcinoma, infantile|Endodermal sinus tumor (morphologic abnormality)|Polyvesicular vitelline tumor|Orchioblastoma|Endodermal sinus tumor|YOLK SAC TUMOR, MALIGNANT|Tumors, Yolk Sac|Tumors, Endodermal Sinus|Yolk sac tumor (disorder)|Endodermal sinus tumour|Endodermal Sinus Neoplasm|Yolk Sac Neoplasm|endodermal sinus tumour|Yolk Sac Tumour Site Unspecified|Tumor, Endodermal Sinus|Tumor, Yolk Sac|endodermal sinus tumor|Yolk Sac Tumor|Hepatoid yolk sac tumour|Endodermal Sinus Tumor|Yolk sac tumour|Carcinoma, Yolk Sac|orchioblastoma|Endodermal Sinus Tumors|Embryonal carcinoma, infantile type|Yolk sac tumor|Yolk Sac Tumor Site Unspecified|Hepatoid yolk sac tumor|yolk sac tumor | Yolk Sac Tumor |
C0014479 | A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. | Efedrina|Ephedrine Erythro Isomer|EPHEDRINE|ephedrine|ePHEDrine|Ephedrine|Ephedrine-containing product|(1R,2S)-2-methylamino-1-phenyl-propan-1-ol|(-)-Ephedrine|L(-)-ephedrine|Product containing ephedrine (medicinal product)|ephedrine products|Ephedrine (substance)|[R-(R*,S*)]-alpha-[1-(Methylamino)ethyl]benzenemethanol|L-Ephedrine|L-erythro-2-(Methylamino)-1-phenylpropan-1-ol|ephedrines|Erythro Isomer of Ephedrine|(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane | ephedrine |
C0035661 | An adrenergic beta-2 agonist used to control PREMATURE LABOR. | Ritodrinium|p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol|Ritodrine (substance)|Ritodrine-containing product|ritodrine|Benzenemethanol, 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, (R*,S*)-|Ritodrina|RITODRINE|Ritodrine|Product containing ritodrine (medicinal product) | ritodrine |
C0282611 | Devices or objects in various imaging techniques used to visualize or enhance visualization by simulating conditions encountered in the procedure. Phantoms are used very often in procedures employing or measuring x-irradiation or radioactive material to evaluate performance. Phantoms often have properties similar to human tissue. Water demonstrates absorbing properties similar to normal tissue, hence water-filled phantoms are used to map radiation levels. Phantoms are used also as teaching aids to simulate real conditions with x-ray or ultrasonic machines. (From Iturralde, Dictionary and Handbook of Nuclear Medicine and Clinical Imaging, 1990) | Phantom, Imaging|phantom|imaging phantom|Imaging Phantom|Imaging Phantoms|Phantom|phantoms|Phantom (physical object) | Phantoms, Imaging |
C1547104 | null | null | Computed radiography |
C0025500 | A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) | Mesothelioma|Mesothelioma, NOS|mesothelioma|mesotheliomas|Mesotheliomas|MESOTHELIOMA | Mesothelioma |
C0024121 | Tumors or cancer of the LUNG. | lung tumours|Lung Tumor|Neoplasm of lung (disorder)|Pulmonary neoplasia|lung tumour|lung tumors|Neoplasm, Pulmonary|Pulmonary Neoplasm|Lungs--Tumors|Tumour of lung|pulmonary neoplasms|Lung Neoplasm|tumour of lung|Tumor of Lung|Pulmonary Neoplasms|Neoplasm, Lung|Neoplasms, Pulmonary|Tumor of lung|Lung Neoplasms|lung neoplasms|LUNG TUMOR|pulmonary neoplasm|Lung tumor|Neoplasm of the Lung|Neoplasm of lung|Neoplasm of Lung|lung neoplasm|Neoplasm of the lung|Neoplasms, Lung|Tumor of the Lung|lung tumor|tumor of lung | Lung Neoplasms |
C0175730 | Any device or component shaped like a hollow cylinder. | tube|Tube Device|TUBE|Tube|Tube, NOS|Tube, device|tubes|Tube, device (physical object) | biomedical tube device |
C0182349 | A positron camera is a device intended to image the distribution of positron-emitting radionuclides in the body. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories. | Positron emission tomography unit, device (physical object)|PET scanner|SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION|PET system|CAMERA, POSITRON|Positron emission tomography unit|Positron emission tomography system (physical object)|pet scanners|pet scanner|Positron emission tomography unit, device|positron camera|Positron emission tomography system | Positron emission tomography unit |
C0444626 | A solid formed by the solidification of a chemical and having a highly regular atomic structure. | Crystal|Crystal Formation|Crystals|crystal structure|crystals|CRYSTALS|Crystalline|crystal|Crystallized|Crystal (substance) | Crystal Structure |
C1514821 | The act of listing or recording officially; officially qualified or enrolled. | Registering|Registration|Registered | Registration |
C0033572 | A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. | GLAND, PROSTATE|Prostatic (qualifier value)|PROSTATE|Prostate gland|Prostatic structure (body structure)|prostatic|Prostata (Glandula prostatica)|Prostatic gland structure|Prostatic gland structure (body structure)|Genital System, Male, Prostate|prostate|Prostatic|Prostate|prostate gland|Prostata|Prostatic structure|Prostatic Gland|Prostato-|PROSTATE GLAND|Prostate Gland|Prostate, NOS|Prostates | Prostate |
C0183335 | null | slab | slabs |
C0180488 | null | Dosimeter|Dosimeter, device|Dosimeter, NOS|Dosimeter, device (physical object)|dosimeter|dosimeters | Dosimeter, device |
C1514743 | The specific medical individual, usually a radiologist, who looks at and interprets a medical image. | READER|Reader | Reader of medical images |
C0700276 | tree section heading for anatomical, physiological, and related terms. | Anatomy|Anatomical Structure|Anatomical structure (body structure)|anatomical structures|biological structure|Biological structure|anatomy|Anatomical structure|anatomic structure|anatomical structure | Anatomic structures |
C0026683 | A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed) | Mucocele|Mucous cyst|mucoceles|mucous retention cyst|mucocele|Mucoceles|Mucous cyst (morphologic abnormality)|Mucous Cyst|mucous cyst|mucinous cyst|MUCOCELE|Mucus Cyst|Mucous retention cyst|mucus cyst|Mucocoele|Mucus cyst|Mucinous cyst | Mucocele |
C0030471 | Air-filled spaces located within the bones around the NASAL CAVITY. They are extensions of the nasal cavity and lined by the ciliated NASAL MUCOSA. Each sinus is named for the cranial bone in which it is located, such as the ETHMOID SINUS; the FRONTAL SINUS; the MAXILLARY SINUS; and the SPHENOID SINUS. | Nasal sinus structure|PARANASAL SINUS|Nasal Sinus|nasal sinuses|ACCESSORY SINUSES|Sinuses, Nasal|Sinuses, Paranasal|sinuses|Accessory sinus cavity, NOS|Set of paranasal sinuses|paranasal sinus cavity|Accessory Sinus|Paranasal sinus|sinus paranasal|Paranasal sinuses set|Accessory sinus cavity|Paranasal sinus, NOS|Accessory Sinuses|Sinus|Nasal and Sinuses|Nasal Sinuses|Nasal sinus structure (body structure)|Paranasal Sinus|nasal sinus|paranasal sinuses|Nasal sinus|Accessory sinus|cavity paranasal sinus|Paranasal sinuses|Nasal sinus, NOS|Accessory sinus, NOS|sinus|cavities paranasal sinus|Paranasal Sinuses|paranasal sinus | Nasal sinus |
C0149507 | Inflammation of the loose connective tissues around the ORBIT, bony structure around the eyeball. It is characterized by PAIN; EDEMA of the CONJUNCTIVA; swelling of the EYELIDS; EXOPHTHALMOS; limited eye movement; and loss of vision. | orbital cellulitis|Orbital cellulitis|cellulitis orbital|Orbital Cellulitis|Postseptal orbital cellulitis|Orbital cellulitis (disorder)|Cellulitides, Orbital|Orbital Cellulitides|CELLULITIS, ORBITAL|Cellulitis, Orbital | Orbital Cellulitis |
C0149663 | A splitting open of an anatomical structure, zone, or organ with the exposure or discharge of its content. | dehiscence|Dehiscence|Dehiscence Of Organ|DEHISCENCE|Dehiscence (morphologic abnormality)|Dehiscence, NOS|dehiscences | Dehiscence |
C1278884 | null | Entire orbital region (body structure)|Entire orbital region|Entire orbit | Entire orbital region |
C0009932 | Groups that serve as a standard for comparison in experimental studies. They are similar in relevant characteristics to the experimental group but do not receive the experimental intervention. | Groups, Control|Control Groups|Control Group|control experiments|Control|control group|Group, Control | Control Groups |
C0008767 | The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries. | Healing scar|Cicatrisation|Scarring|scarring|scarring skin|Cicatrization|healing scar|SKIN SCARRING|healing scars|skin scarring|scarred skin|cicatrization|cicatrisation | Cicatrization |
C0282002 | null | null | Superficial Infection |
C0040145 | Surgical removal of the thyroid gland. (Dorland, 28th ed) | Thyroidectomies|THYROID GLAND: EXCISIONS|THYROIDECTOMY|Thyroid gland excision|thyroidectomies|Excision of thyroid gland|procedures thyroidectomy|Thyroidectomy, NOS|Thyroidectomy|thyroidectomy|Thyroidectomy (procedure) | Thyroidectomy |
C0018021 | Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency (HYPOTHYROIDISM), or hormone overproduction (HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic (GOITER, ENDEMIC). | THYROMEGALY|Struma - goitre|Goiter|goiter|Goiter (disorder)|enlarged thyroid gland|Enlargement of thyroid|Thyroid goitre|THYROID ENLARGED|thyroid goiter|thyromegaly|Thyroid goiter|THYROID ENLARGEMENT|Enlarged thyroid gland in neck|Goiter, NOS|enlarged thyroid|Struma - goiter|Enlarged thyroid gland|goitres|Struma of thyroid|Goitre|Goiter, unspecified|thyroid gland swelling|Thyromegaly|Thyroid enlargement|struma|goiters|GOITRE|enlargement of thyroid|Goitre, NOS|GOITER|swelling thyroid gland|Enlarged thyroid gland (finding)|Swelling of thyroid gland|thyroid enlargement|Goiters|goiter thyroid|goitre | Goiter |
C0001883 | Any hindrance to the passage of air into and out of the lungs. | Airway obstruction|Respiratory obstruction (disorder)|obstruction airway|airways obstruction|Airway obstruction, NOS|Airway Obstruction|airway obstruction|Airway Obstructions|airway obstructions|Respiratory obstruction|respiratory obstruction|Obstruction, Airway|Embarrassed airway|Obstructions, Airway | Airway Obstruction |
C0877414 | null | goiter malignant | malignant goiter |
C0945826 | null | Ambulation|ambulation | Ambulation |
C0013080 | A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) | Trisomy 21|Down syndrome|47,XY,+21|Complete trisomy 21 syndrome (disorder)|Syndrome, Down|T21 - Trisomy 21|Complete trisomy 21 syndrome|TRISOMY 21 SYNDROME|TRISOMY 21|Down's Syndrome|Down's syndrome|21 trisomy|Down Syndrome|downing syndrome|Trisomy G|Downs Syndrome|MONGOLISM|mongolism|SYNDROME DOWN'S|down s syndrome|DOWN SYNDROME|mongoloidism|Downs syndrome|Trisomy 21 (morphologic abnormality)|Chromosomal imbalance syndrome, pair 21, trisomy|trisomy 21|G Trisomy|Trisomy 21 syndrome|47,XX,+21|Syndrome, Down's|21 trisomies|DOWN'S SYNDROME|trisomy 21 syndrome|morbus down|Mongolism|Trisomy 21 (Down Syndrome)|MONGOLOIDISM|Trisomy 21 Syndrome | Down Syndrome |
C1285162 | A disorder characterized by the progressive loss of function and/or structure of the affected tissues. | degenerative disorders|Degenerative Disease|Degenerative Disorder|degenerative disorder|degenerative disease|Degenerative disorder (disorder) | Degenerative disorder |
C0032357 | A syndrome which is characterized by symbrachydactyly and aplasia of the sternal head of pectoralis major. | Poland's syndrome|Poland Anomaly|Poland anomaly|polands syndrome|anomaly polands|POLAND'S SYNDROME|Syndrome, Poland|Syndactyly, Poland|Unilateral defect of pectoralis muscle and syndactyly of hand|poland anomaly|SYNDROME POLANDS|POLAND SYNDACTYLY|Poland sequence|POLAND ANOMALY|Poland anomaly (disorder)|poland's anomaly|poland's syndrome|Poland's anomalad|Poland syndrome|Poland Syndactyly|POLAND SYNDROME|Poland Syndrome|Poland anomalad|Poland's syndactyly|Poland Sequence|POLAND SEQUENCE|Unilateral defect of pectoralis muscle AND syndactyly of hand|poland syndrome|Anomaly, Poland | Poland Syndrome |
C0334077 | null | null | Unilateral hypoplasia |
C1305714 | null | Entire anterior chest wall|Entire anterior chest wall (body structure) | Entire anterior chest wall |
C1458140 | A coagulation disorder characterized by a tendency for excessive bleeding. | Bleeding Predisposition|BLEEDING TENDENCY|Bleeding tendencies|Hemorrhagic diathesis|Bleeding Disorders|Bleeding disorder|Bleeding Tendency|BLEEDING DISORDER|Bleeding tendency|bleeding abnormal|abnormal bleeding|Bleeding Diathesis|Bleeding diathesis|Bleeding Disorder|Abnormal bleeding|Tendency to bleed (observable entity)|Tendency to bleed | Bleeding tendency |
C0015915 | An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro. | In Vitro Fertilizations|IVF|In vitro fertilization procedure|Test tube ovum fertilization (procedure)|Test Tube Fertilization|In vitro fertilisation|In vitro fertilisation procedure|Test-Tube Fertilizations|Other Procedures @ Physiological Systems and Anatomical Regions @ Other Procedures @ None @ External @ Other Method @ In Vitro Fertilization|in vitro fertilization|Fertilization in Vitro|Test-Tube Fertilization|fertilisation in vitro|In vitro fertilization|Fertilization in vitro|test-tube fertilization|In Vitro Fertilization|Artificial Fertilization|fertilization in vitro|Test tube baby technique|in vitro fertilization (IVF)|Fertilization, Test-Tube|Fertilizations in Vitro|Test tube ovum fertilization|Test tube ovum fertilisation|in vitro fertilisation|artificial fertilization|Fertilizations, Test-Tube | Fertilization in Vitro |
C0429470 | null | Ovulatory (finding)|Ovulatory cycle|ovulatory cycle|ovulatory | Ovulatory |
C0949385 | Use of gonadotropins to stimulate follicular growth, oocyte maturation, and the release of an ovum or ova (SUPEROVULATION). | Ovarian Stimulations|ovarian stimulation|Stimulations, Ovarian|Stimulation, Ovarian | Ovarian Stimulation |
C0278704 | A malignant tumor that occurs in children. Representative examples include soft tissue and bone sarcomas (e.g. osteosarcoma) and embryonal neoplasms (e.g. hepatoblastoma and rhabdoid tumor). | pediatric cancer|cancer pediatric|cancers childhood|Malignant Pediatric Tumor|cancers pediatric|pediatric neoplasm|childhood cancer|cancer, childhood|Pediatric Cancer|cancer pediatrics|Cancer in Children|Malignant Neoplasm|cancer childhood|Malignant Childhood Tumor|Childhood Malignant Neoplasm|Malignant Childhood Neoplasm|Malignant Pediatric Neoplasm|Childhood Cancer|Cancer in children|pediatric neoplasm/cancer | Malignant Childhood Neoplasm |
C0036597 | A feeling of self-worth, self-confidence, and self-respect. | Esteem, Self|self-esteem|self esteem|Self Esteems|Self Esteem|Self-esteem (observable entity)|Self-esteem | Self Esteem |
C0009871 | Chemical substances that prevent or reduce the probability of CONCEPTION. | Contraceptive agent|Contraceptive Agents|contraceptives|contraceptive agent|Contraceptives|contraceptive drugs|birth control agent|contraceptive agents|contraceptive drug|contraceptive|Agents, Contraceptive|Medicinal product acting as contraceptive (product)|Contraceptive drugs | Contraceptive Agents |
C0236075 | Any of the mental or physical manifestations that accompany perimenopause and menopause. | symptoms, menopausal|menopausal symptoms|Menopausal symptom (finding)|Menopausal symptom, NOS|Menopausal Symptom|Menopausal Symptoms|menopausal symptom | Menopausal symptom |
C0014939 | Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. | Estrogens|Estrogenic drug, NOS|Estrogen Receptor Agonists|Agents, Estrogenic|estrogenic preparation|estrogen products|oestrogens|Product containing estrogen (product)|Estrogen (substance)|Compounds, Estrogenic|Estrogenic Agents|Oestrogens|Estrogen|Estrogen preparation, NOS|Receptor Agonists, Estrogen|ESTROGENS|Therapeutic Estrogen|estrogens|Estrogen-containing product|oestrogen|oestrogen products|estrogen substance|Estrogen preparation|Oestrogen preparation, NOS|Estrogenic Compounds|Agonists, Estrogen Receptor|estrogen|ESTROGENIC PREPARATIONS|Estrogen, NOS|Oestrogen, NOS|Oestrogenic drug, NOS | estrogens |
C0014180 | The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. | mucous membrane lining inside the uterus|ENDOMETRIUM|Tunica mucosa (Endometrium)|endometria|Endometria|Endometrium|endometriums|Endometrial structure|endometrium|Tunica Mucosa|Tunica mucosa uteri|Endometrium, NOS|Endometrial structure (body structure) | Endometrium |
C0008543 | Salts of chromic acid containing the CrO(2-)4 radical. | chromates|chromate|chromated|CHROMATES | Chromates |
C0034435 | Hydrocarbon rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups. | Quinones|Benzoquinone Compound|quinone|Quinone Compound | Quinones |
C0097109 | A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 4 by cytochrome P450 1B1, with potential carcinogenic activity. The mechanism of action for the tumor promoting activity of 4-hydroxyestradiol (4-OHE2) is not entirely known but this metabolite undergoes metabolic redox cycling with its oxidized quinoid form, estradiol 3,4-quinone, and generates reactive oxygen species (ROS), which induce oxidative DNA damage. 4-OHE2 also activates nuclear factor-kappaB (NF-kB) and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways, and induces the expression of certain genes through activation of the estrogen receptor (ER), which stimulates cellular proliferation in susceptible cells. | Estra-1,3,5(10)-Triene-3,14,17beta-Triol|4-Hydroxyestradiol-17beta|3,4,17beta-Estriol|4OHE2|4-Hydroxy-17-Beta-Estradiol|3,4,17beta-Trihydroxy-1,3,5[10]-Estratriene|4-OH-Estradiol|4-hydroxyestradiol-17 beta|4-Hydroxyestradiol|4-HYDROXYESTRADIOL|4-OHE2 | 4-hydroxyestradiol |
C0034804 | Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. | Estrogen Receptors|ER|ER Family|estrogen receptor (ER)|Nuclear Receptor Subfamily 3 Group A|oestrogen receptor|estrogen receptors|Oestrogen receptor site|Estrogen receptor site|E2R - estrogen receptor|Estradiol Receptor|Estrogen Receptor Family|Receptors, Estrogen|Estrogen Receptor Family Protein|Estrogen receptor|NR3A|estrogen receptor|Estrogen Receptor|Estrogen receptor (substance)|Estrogen--Receptors | Estrogen Receptors |
C0858970 | null | carcinogenicity | Carcinogenicity |
C1512423 | Exhibiting a cyclic structure containing at least one amino (NH2) group, some Heterocyclic Amines are carcinogenic chemicals formed from cooking meat such as beef, pork, fowl, and fish when amino acids and creatine (found in muscle) react at high temperatures. About 17 identified heterocyclic amines that result from cooking meat may increase human cancer risk. Because of the high temperatures used, frying, broiling, and barbecuing produce the largest amounts of heterocyclic amines. (NCI04) | HCA|HAA|Heterocyclic Aromatic Amines|Heterocyclic Amines|heterocyclic amine|Heterocyclic Aromatic Amine | Heterocyclic Amines |
C0665341 | One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA. | Estradiol Receptor alpha|Receptor alpha, Estradiol|ERalpha|Estrogen Receptors alpha|alpha, Estradiol Receptor|estrogen receptor alpha|Estrogen Receptor alpha|Receptor alpha, Estrogen | Estrogen Receptor alpha |
C1512505 | Cells found in human breast cancers or extracted from cancers as established cell lines | Human Breast Cancer Cell|Human Breast Cancer Cells | Breast Cancer Cell |
C0045811 | A synthetic, gray-white crystalline solid that is soluble in dimethylsulfoxide and methanol. It is produced in small quantities for research purposes. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is formed naturally during the cooking of muscle-derived foods (meat and fish). Levels of this chemical produced in this manner are dependent on cooking temperature, cooking time and method of cooking (direct or indirect). It is one of the most abundant heterocyclic amines in a typical Western diet. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine has also been detected in processed food flavorings, beer, wine, and cigarette smoke. It is reasonably anticipated to be a human carcinogen. (NCI05) | 2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE|2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine|phip|2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine|2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine|2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine|PHIP|1-methyl-6-phenyl-1h-imidazo(4,5-b)pyridin-2-amine|2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP)|PhIP | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine |
C1458155 | Tumors or cancer of the human BREAST. | Neoplasm of the breast|breast tumours|breast tumour|tumor of breast|Neoplasia of the breast|Tumor of breast|Neoplasm of Breast|Tumor, Breast|BREAST NEOPLASM|Breast Tumors|Tumour of breast|Neoplasm of breast (disorder)|Breast Neoplasm|Breast Neoplasms|Tumor of the Breast|breast neoplasm diagnosis|Breast Tumor|Breast tumor|mammary tumor|Breast tumour|breast tumors|Breast--Tumors|Neoplasm of breast|breast neoplasm|breast tumor|Tumours of the breast|NEOPLASM BREAST|Tumor of Breast|Neoplasms, Breast|Tumors, Breast|Neoplasm of the Breast|Neoplasm, Breast|breast neoplasms | Mammary Neoplasms |
C0597565 | group of chemical compounds formed from ammonia by replacement of three of the hydrogen atoms by hydrocarbon radicals. | tertiary amine|amines tertiary | tertiary amine |
C0430054 | null | poisoning screening|Toxicology elimination screening panel|Toxicology screen|screening toxicology|toxicology screen|Toxicology screen, general, NOS|toxicology screening|screen toxicology|screens toxicology | Toxicology screen, general (procedure) |
C0005117 | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. | BERBERINE|Berberine (substance)|Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-|Product containing berberine (medicinal product)|Berberine-containing product|Umbellatine|Berberine|berberine | berberine |
C0069963 | null | 5,6-dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium|PALMATINE|berbericinine|palmatine|Palmatine|palmatine ion|palmatine cation|o,o-dimethyldemethyleneberberine | palmatine |
C0050078 | A major spontaneous oxidized derivative of 2'-deoxyguanosine and a biomarker of oxidative DNA damage. 8-hydroxy-2'-deoxyguanosine (8-oxo-dG) is formed through the reaction of guanine with reactive oxygen species. Although normally repaired and removed by the base excision repair mechanism, 8-oxo-dG can potentially mispair with deoxyadenine leading to G-to-T transversion mutations, which cause frequent recombinations and single nucleotide polymorphisms (SNPs) in the human genome. The concentration of 8-oxo-dG within a cell is a measurement of oxidative stress and may thus be used to assess the extent of physiological and environmental damage to DNA. | 8-OHdG|8 Oxo Deoxyguanosine|8-Hydroxy-2'-Deoxyguanosine|2'-Deoxy-8-Oxoguanosine|8-oxo-dGuo|2' Deoxy 8 Oxoguanosine|8-oxodG|8-hydroxy-deoxyguanosine (substance)|8-Oxo-dG|8-OH-dG|8OHdG|2-Amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione|8-Oxo-7,8-Dihydro-2'-Deoxyguanosine|7,8-Dihydro-8-Oxo-2'-Deoxyguanosine|7,8 Dihydro 8 Oxo 2' Deoxyguanosine|8-hydroxydeoxyguanosine|2'-Deoxy-7,8-Dihydro-8-Oxoguanosine|8-Oxo-7,8-dihydro-2'-deoxyguanosine|8-hydroxy-deoxyguanosine|8 Oxo 2' Deoxyguanosine|8-Hydroxy-2'-deoxyguanosine|8-oxodGuo|8 Hydroxy 2' Deoxyguanosine|8-Hydroxy-2-deoxyguanosine|8-Oxo-2'-Deoxyguanosine|8 Hydroxydeoxyguanosine|8-Hydroxydeoxyguanosine|8-Oxo-Deoxyguanosine|8-oxo-dG|2' Deoxy 8 Oxo 7,8 Dihydroguanosine|8 Oxo 7,8 Dihydro 2' Deoxyguanosine|2' Deoxy 7,8 Dihydro 8 Oxoguanosine|2' Deoxy 8 Hydroxyguanosine|2'-Deoxy-8-Oxo-7,8-Dihydroguanosine|2'-Deoxy-8-Hydroxyguanosine | 8-Hydroxy-2'-Deoxyguanosine |
C0066117 | null | methylmercaptopropionaldehyde|3-(methylthio)propionaldehyde | methional |
C0074721 | A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed) | Sodium azide|NaN3|Azide, Sodium|sodium azide|Sodium azide (substance) | Sodium Azide |
C0008574 | A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens. | Cr - Chromium|Cr|Chromium, elemental|Chromium (substance)|Cr element|Chrom|Cromo|Chromium|CHROMIUM|Chromium, NOS|chromium|Dinakrome | chromium |
C0005390 | null | bile acids|Bile acid, NOS|Bile Acids|bile acid|Product containing bile acid (product)|acid bile|Acids, Bile|acids bile|Bile acid (substance)|Bile acid-containing product|Bile acids|Bile acid|acid bile salts | Bile Acids |
C0068241 | null | null | N-nitrosotaurocholic acid |
C0026029 | Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) | Microsomes|microsomes|Endoplasmic reticulum vesicle|microsome|Microsome | Microsomes |
C0245514 | A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. | Troglitazone (substance)|Troglitazone|5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione|5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione|TROGLITAZONE|2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-|5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T|Troglitazone-containing product|Product containing troglitazone (medicinal product)|5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione|troglitazone|Troglitazona | troglitazone |
C0245514 | A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. | Troglitazone (substance)|Troglitazone|5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione|5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione|TROGLITAZONE|2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-|5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T|Troglitazone-containing product|Product containing troglitazone (medicinal product)|5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione|troglitazone|Troglitazona | troglitazone |
C1513528 | null | null | Mouse Cell Line |
C0006507 | A di-tert-butyl PHENOL with antioxidant properties. | 2,6-ditert-butyl-4-cresol (BHT)|Dibutylhydroxytoluene|2,6-Bis(1,1-dimethylethyl)-4-methylphenol|Butylated hydroxytoluene (substance)|Hydroxytoluene, Butylated|BHT|BHT - Butyl hydroxytoluene|BUTYLATED HYDROXYTOLUENE|Butyl hydroxytoluene (BHT)|Di tert butyl methylphenol|4-Methyl-2,6-ditertbutylphenol|Butylhydroxytoluene|Phenol, 2,6-bis(1,1-dimethylethyl)-4-methyl-|bht|2,6-Di-t-butyl-4-methylphenol|2,6 Di t butyl 4 methylphenol|butylated hydroxytoluene (BHT)|Product containing butylated hydroxytoluene (medicinal product)|butylated hydroxytoluene|2,6-ditertiary-butyl-4-cresol (BHT)|2,6-Di-tert-butyl-p-cresol|Butylated hydroxytoluene|Butyl hydroxytoluene|4 Methyl 2,6 ditertbutylphenol|2,6-di-tert-butyl-p-cresol|2,6-Di-tert-butyl-4-cresol|2,6 Di tert butyl 4 methylphenol|Butylated Hydroxytoluene|2,6-Di-tert-butyl-4-methylphenol|2,6 Di tert butyl p cresol|Butylated hydroxytoluene-containing product|Di-tert-butyl-methylphenol|2,6-Di-tert-butyl-1-hydroxy-4-methylbenzene | butylated hydroxytoluene |
C0006507 | A di-tert-butyl PHENOL with antioxidant properties. | 2,6-ditert-butyl-4-cresol (BHT)|Dibutylhydroxytoluene|2,6-Bis(1,1-dimethylethyl)-4-methylphenol|Butylated hydroxytoluene (substance)|Hydroxytoluene, Butylated|BHT|BHT - Butyl hydroxytoluene|BUTYLATED HYDROXYTOLUENE|Butyl hydroxytoluene (BHT)|Di tert butyl methylphenol|4-Methyl-2,6-ditertbutylphenol|Butylhydroxytoluene|Phenol, 2,6-bis(1,1-dimethylethyl)-4-methyl-|bht|2,6-Di-t-butyl-4-methylphenol|2,6 Di t butyl 4 methylphenol|butylated hydroxytoluene (BHT)|Product containing butylated hydroxytoluene (medicinal product)|butylated hydroxytoluene|2,6-ditertiary-butyl-4-cresol (BHT)|2,6-Di-tert-butyl-p-cresol|Butylated hydroxytoluene|Butyl hydroxytoluene|4 Methyl 2,6 ditertbutylphenol|2,6-di-tert-butyl-p-cresol|2,6-Di-tert-butyl-4-cresol|2,6 Di tert butyl 4 methylphenol|Butylated Hydroxytoluene|2,6-Di-tert-butyl-4-methylphenol|2,6 Di tert butyl p cresol|Butylated hydroxytoluene-containing product|Di-tert-butyl-methylphenol|2,6-Di-tert-butyl-1-hydroxy-4-methylbenzene | butylated hydroxytoluene |
C0032428 | null | Polyacrylamide Gel Electrophoresis, Two Dimensional|2D PAGE|2-D Polyacrylamide Gel Electrophoresis|2 D Polyacrylamide Gel Electrophoresis|PAGE, 2D|Polyacrylamide Gel Electrophoresis, 2D|Polyacrylamide Gel Electrophoresis, Two-Dimensional|Polyacrylamide Gel Electrophoresis, 2 D|Polyacrylamide Gel Electrophoresis, 2-D | 2D Polyacrylamide Gel Electrophoresis |
C0037813 | An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. | mass spectrography|Mass spectrometry measurement|mass spectrum analysis|Spectrometry, Mass|MassSpec|Analysis, Mass Spectrum|Spectrum Analysis, Mass|Mass spectrometry measurement (procedure)|Mass spectrometry measurement, NOS|Photometry/Spectrum Analysis, Mass|mass spectrometry|Mass Spec|Mass Spectrum Analyses|Mass spectroscopy measurement, NOS|MASS SPECTROMETRY|Mass spectrometry|Spectrum Analyses, Mass|Mass Spectrometry|Mass Spectrum|Mass spectroscopy measurement|Mass Spectroscopy|MS|Analyses, Mass Spectrum|Mass Spectrum Analysis|Spectroscopy, Mass|mass spectroscopy | Mass Spectrometry |
C0018850 | Proteins which are synthesized in eukaryotic organisms and bacteria in response to hyperthermia and other environmental stresses. They increase thermal tolerance and perform functions essential to cell survival under these conditions. | stress protein|hsp|heat-shock protein|Heat Shock Protein|Heat shock proteins|Heat-Shock Protein|heat shock proteins|Stress Proteins|HSP|Heat Shock Proteins|Heat-Shock Proteins|heat shock protein | Heat shock proteins |
C0041348 | A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. | Tubulin|Tubulins|tubulin|Tubulin (substance) | Tubulin |
C0045583 | null | 2,6-bis(1,1-dimethylethyl)-4-methylene-2,5-cyclohexadien-1-one|BHT-QM|BHT-quinone methide | 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone |
C0005329 | Liquids that are suitable for drinking. (From Merriam Webster Collegiate Dictionary, 10th ed) | Beverage|beverage|beverages|beverage type|Beverages | Beverages |
C0034338 | An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. | PYRUVALDEHYDE|Pyruvaldehyde|Propanal, 2-oxo-|Pyruvic Aldehyde|methyl glyoxal|Methylglyoxal|Aldehyde, Pyruvic|Acetylformaldehyde | pyruvaldehyde |
C0597410 | A chromatography technique in which the stationary phase is composed of a non-polar substance with a polar mobile phase, in contrast to normal-phase chromatography in which the stationary phase is a polar substance with a non-polar mobile phase. | Reverse-Phase Chromatography|Reversed Phase Chromatography|Chromatography, Reversed-Phase|Chromatography, Reverse Phase|reversed phase chromatography|Reversed-Phase Chromatography|Reverse Phase Chromatography | Chromatography, Reverse-Phase |
C0010957 | null | damages|tissue damage|Tissue damage, NOS|Damage|Tissue Damage|damages tissue|Damage, Tissue|Damage, NOS|damage|Tissue damage|damage tissues|Damage (morphologic abnormality) | Tissue damage |
C0020600 | An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent. | Hypochlorous acid|Hypochlorous Acid|Hypochlorous acid (substance)|hypochlorous acid|HYPOCHLOROUS ACID | hypochlorous acid |
C0033607 | Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). | Product containing peptide hydrolase inhibitor (product)|peptidase inhibitors|Antagonists, Protease|antiprotease|Substance with peptide hydrolase inhibitor mechanism of action (substance)|Peptidase Inhibitors|Inhibitors, Peptidase|Protease inhibitors|Endopeptidase Inhibitors|Inhibitors, Endopeptidase|Antiproteases|Protease Inhibitor|Hydrolase Inhibitors, Peptide|Substance with peptide hydrolase inhibitor mechanism of action|Inhibitors, Protease|Peptide hydrolase inhibitor|Inhibitors, Peptide Hydrolase|proteinase inhibitor|protease inhibitors|Peptide Peptidohydrolase Inhibitors|Peptidohydrolase Inhibitors, Peptide|inhibitors protease|Peptide Hydrolase Inhibitors|protease inhibitor|Peptide hydrolase inhibitor-containing product|Protease Inhibitors|Inhibitor, Protease|Protease Antagonists|Inhibitors, Peptide Peptidohydrolase | Protease Inhibitors |
C0047299 | null | CAPADP | 3-chloroacetylpyridine adenine dinucleotide phosphate |
C0047299 | null | CAPADP | 3-chloroacetylpyridine adenine dinucleotide phosphate |
C0007103 | Primary or metastatic malignant neoplasm involving the endometrium (mucous membrane that lines the endometrial cavity). | Malignant neoplasm of endometrium|Endometrial Cancer|Endometrial cancer|Malignant Endometrial Neoplasm|endometrial cancer|ENDOMETRIAL NEOPLASM MALIGNANT|cancer of the endometrium|cancer of endometrium | Malignant neoplasm of endometrium |
C0039286 | One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. | (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine|Tamoxifeno|Tamoxifen-containing product|Tamoxifen (substance)|Tamoxifen|Product containing tamoxifen (medicinal product)|TAMOXIFEN|1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene|Tamoxifenum|1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|Tamoxifène|TAM|1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine|tamoxifen|Tamoxifene|Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)- | tamoxifen |
C0051555 | A natural polyketide isolated from the myxobacteria Sorangium cellulosum with antifungal activity. Ambruticin interferes with the osmoregulatory system by activating fungal high osmolarity glycerol (HOG) pathway. This results in an accumulation of intracellular glycerol, which in turn causes water influx and swelling of the cell. This ultimately leads to cellular leakage and cell death. | AMBRUTICIN|Ambruticin|5,6-dihydroxypolyangioic acid | ambruticin |
C0051555 | A natural polyketide isolated from the myxobacteria Sorangium cellulosum with antifungal activity. Ambruticin interferes with the osmoregulatory system by activating fungal high osmolarity glycerol (HOG) pathway. This results in an accumulation of intracellular glycerol, which in turn causes water influx and swelling of the cell. This ultimately leads to cellular leakage and cell death. | AMBRUTICIN|Ambruticin|5,6-dihydroxypolyangioic acid | ambruticin |
C0001555 | Used with drugs for dosage forms, routes of administration, frequency and duration of administration, quantity of medication, and the effects of these factors. | administration & dosage|administration and dosage | administration & dosage |
C0067113 | A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05) | N-NITROSONORNICOTINE|1'-Nitrosonornicotine|Pyridine, 3-(1-nitroso-2-pyrrolidinyl)-, (S)-|N-nitrosonor-nicotine|Nitrosonornicotine|nitrosonornicotine|NNN|3-(1-Nitroso-2-pyrrolidinyl)pyridine|(S)-N'-nitrosonornicotine|anti-N'-nitrosonornicotine|1'-Demethyl-1'-nitroso-nicotine|N-nitrosonornicotine | N'-nitrosonornicotine |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.